Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

L'Hospitalet de Llobregat, Spain Clinical Trials

A listing of L'Hospitalet de Llobregat, Spain clinical trials actively recruiting patients volunteers.

RESULTS

Found (752) clinical trials

Validity of 1BPM for Diagnosis of Hypertension

Blood pressure measurement methods and conditions are determinants of hypertension diagnosis. The classical methods such as office blood pressure measurement (OBPM) and home blood pressure monitoring (HBPM) have significant limitations. A recent British guideline recommends systematic 24-hour ambulatory blood pressure monitoring (ABPM). However, these devices are not available at all ...

Phase N/A

1.07 miles

Learn More »

Perifoveal Vascular Network Assessed by OCT-Angiography in Type I Diabetes Mellitus

Diabetic retinopathy (DR) is the leading cause of blindness in type 1 Diabetes Mellitus (DM) patients, as a consequence of impaired blood flow in the retina. Optical coherence tomography angiography (OCT-A) is a newly developed, non-invasive, retinal imaging technique that allows detection of perfused and non perfused areas of the ...

Phase N/A

1.07 miles

Learn More »

Conversion Pharmacodynamic Study in Stable Renal Transplant Patients Receiving Tacrolimus Two Times a Day to a New Formulation of Tacrolimus - LCP Tacro - 1 Time a Day.

LCP-Tacro is an extended-release formulation of tacrolimus designed for once-daily dosing. Phase 1 studies demonstrated greater bioavailability than twice-daily tacrolimus capsules and no new safety concerns. Stable kidney transplant patients can be safely converted from Adoport twice-daily to LCP-Tacro. The greater bioavailability of LCP-Tacro after once-daily dosing results in similar ...

Phase

1.07 miles

Learn More »

Peripheral Physiological Measures as Determinants of Pain Risk

Using MEM for peripheral sensory and motor axons we want to identify a set of excitability measures that: Correlate with parameters of clinical pain and of pain processing in existing pain patients (cross sectional study), with the aim to obtain an objective Pain Biomarker. Predict development of neuropathic pain in ...

Phase N/A

1.07 miles

Learn More »

Efficacy and Safety of PRJ212 to Improve the Memory of Patients With Mild Severity Alzheimer's Disease

Men and women from 60 to 85 years old with diagnosis of mild severity Alzheimer's disease, according to the diagnostic criteria established by the National Institute of Neurological and Communicative Disorders and Stroke and Alzheimer's Disease and Related Disorders Associations (NINCDS-ADRDA).

Phase N/A

1.07 miles

Learn More »

Study of LM11A-31-BHS in Mild-moderate AD Patients

The goal of this AD Pilot is to conduct a prospective, double-blind, multicenter, phase IIa exploratory safety, feasibility and proof-of-concept trial in mild to moderate Alzheimer's disease patients with the orally bioavailable p75 neurotrophin receptor ligand LM11A-31-BHS dosed twice daily for 26 weeks. Successful completion of this trial will provide ...

Phase

1.07 miles

Learn More »

Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLC

The purpose of this study is to find out whether it is better to receive a new drug, MEDI4736, or better to receive no further treatment after surgery (and possibly chemotherapy) for lung cancer.

Phase

1.07 miles

Learn More »

Analysis of Soluble Mediators Cytokines and Circulating Angiogenic Factors (FACs) as Potential Predictors / Prognostic Factors in Advanced Non-squamous Lung Carcinoma

Current management of patients with locally advanced or metastatic NSCLC, with no susceptible molecular alterations (EGFR mutation, ALK translocation, ROS1 fusion), includes combinations based on platinum in the first line of treatment, while in the second Line, there are three possibilities in monotherapy: docetaxel, erlotinib and pemetrexed. Pemetrexed is exclusively ...

Phase N/A

1.07 miles

Learn More »

Efficacy and Safety Study of Gantenerumab in Participants With Early Alzheimer's Disease (AD)

This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the efficacy and safety of gantenerumab versus placebo in participants with early (prodromal to mild) AD. All participants must show evidence of beta-amyloid pathology. Eligible participants will be randomized 1:1 to receive either subcutaneous (SC) injection of gantenerumab or placebo. The primary ...

Phase

1.07 miles

Learn More »

An Efficacy Safety and Pharmacokinetics Study of JNJ-56136379 in Participants With Chronic Hepatitis B Virus Infection

The main study consists of 2-parts and each part will consist of 2 types of Chronic Hepatitis B-infected participant populations. Each part of the study will consist of screening phase (up to 8 weeks), treatment phase (24 weeks or 48 weeks, depending on treatment response), and post-treatment follow-up phase (24 ...

Phase

1.07 miles

Learn More »